Anti-p185HER2 monoclonal antibodies: biological properties and potential for immunotherapy.
Park
J W
JW
Stagg
R
R
Lewis
G D
GD
Carter
P
P
Maneval
D
D
Slamon
D J
DJ
Jaffe
H
H
Shepard
H M
HM
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000235:genetics*; D002455:Cell Division; D002986:Clinical Trials as Topic / Q000379:methods; D005784:Gene Amplification; D006801:Humans; D007457:Iodine Radioisotopes / Q000008:administration & dosage / Q000627:therapeutic use; D008325:Mammary Neoplasms, Experimental / Q000000981:diagnostic imaging / Q000235:genetics / Q000532:radiotherapy / Q000628:therapy; D051379:Mice; D009363:Neoplasm Proteins / Q000235:genetics / Q000276:immunology* / Q000502:physiology; D009368:Neoplasm Transplantation; D011379:Prognosis; D011518:Proto-Oncogene Proteins / Q000235:genetics / Q000276:immunology* / Q000502:physiology; D011519:Proto-Oncogenes; D016719:Radioimmunodetection; D016499:Radioimmunotherapy; D018719:Erb-b2 Receptor Tyrosine Kinases; D011993:Recombinant Fusion Proteins / Q000276:immunology; D014183:Transplantation, Heterologous; D014407:Tumor Cells, Cultured
D000911:Antibodies, Monoclonal; D007457:Iodine Radioisotopes; D009363:Neoplasm Proteins; D011518:Proto-Oncogene Proteins; D018719:Erb-b2 Receptor Tyrosine Kinases; D011993:Recombinant Fusion Proteins